Last Updated : December 23, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Keytruda | pembrolizumab | Colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Classical Hodgkin lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Renal cell carcinoma, adjuvant | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Gastric or gastroesophageal junction adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Biliary tract carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Melanoma Adjuvant Treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Primary mediastinal B-cell lymphoma | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Keytruda | Pembrolizumab | Advanced non-small cell lung carcinoma (first line) | Reimburse with clinical criteria and/or conditions | Complete |